Platforms

R&D

Scroll To Explore

Our approach

 

We address unmet needs in immuno-oncology, CNS and rare diseases using the following strategies:

→ Identifying and validating new therapeutic GPCR targets
→ Designing allosteric modulators presenting better efficacy
→ Selecting biased ligands presenting better safety profile
→ Addressing orphan and historically intractable GPCRs
→ Increasing the success rate of High Throughput Screening (HTS) campaigns

 

 

Platforms
Technologies